SS Innovations International Inc (OTC: SSII) is a surgical robotics company that designs, manufactures, and sells the SSi Mantra robotic surgical system to hospitals and healthcare facilities. Revenue comes from capital equipment sales of the SSi Mantra system, with a direct sales organization of ten capital sales representatives and thirty clinical support staff as of the 10-K filed 2026-03-10. The company manufactures systems at an approximately 75,000 square-foot facility in Gurugram, Delhi NCR, India, with production capacity of 20 systems per month. SSII holds CDSCO regulatory approval in India, including approval for telesurgery and tele-proctoring procedures received in December 2024, and has received regulatory approvals in Colombia, Ecuador, Guatemala, Indonesia, Kenya, Oman, Philippines, Sri Lanka, Ukraine, and the United Arab Emirates. As of December 31, 2025, the company had performed more than 120 telesurgeries using the SSi Mantra. A 510(k) premarket notification was submitted to the FDA on December 5, 2025, covering general, urological, colorectal, gynecological, and cardiac surgery.

Revenue model

Transactional capital equipment sales of the SSi Mantra robotic surgical system to hospitals and healthcare facilities. Each initial system sale is a major capital purchase with a lengthy sales cycle. The filing also references deferred revenue on the balance sheet as of December 31, 2025, suggesting some service or support revenue components, though specific figures are not disclosed in the excerpts.

Products and services

SSi Mantra robotic surgical system, approved for use across multiple specialties including general, urological, colorectal, gynecological, and cardiac surgery. The system supports telesurgery and tele-proctoring procedures. Related services include installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring. The company also sells instruments used in procedures performed on the SSi Mantra platform.

Customers and end markets

Customers are hospitals and healthcare facilities, including individual hospitals and integrated hospital chains. End markets span multiple surgical specialties: cardiac, urology, gynecology, colorectal, and general surgery. Primary geography served to date is India, with limited international marketing activity as of the filing date.

Value-chain role

Vertically integrated manufacturer and direct seller of robotic surgical systems. The company designs and manufactures its own systems in-house in Gurugram, India, employs a direct capital sales force, and maintains a field service and clinical support organization. It is establishing distributor relationships internationally.

Geographic exposure

Headquartered and manufacturing in Gurugram, Delhi NCR, India. Holds regulatory approvals in India, Colombia, Ecuador, Guatemala, Indonesia, Kenya, Oman, Philippines, Sri Lanka, Ukraine, and the United Arab Emirates as of the 10-K filed 2026-03-10. ISO 13485 approval and Indian export license allow marketing in 50 non-FDA, non-EU countries without further approvals. An additional 79 countries require only minimal registration. FDA 510(k) submission made December 5, 2025.

Source: SEC 10-K, filed 2026-03-10

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Alphatec Holdings Inc AtriCure Inc Axonics, Inc. Enovis Corp Integer Holdings Corp NUVASIVE INC Omnicell Inc Tandem Diabetes Care Inc Transmedics Group Inc